XERS:NASDAQXeris Biopharma Holdings, Inc. Analysis

Xeris Biopharma posted a robust 38% revenue growth to $315 M in Q1 2026, driven by a near‑doubling of Recorlev sales and modest gains in Keveyis, while maintaining an impressive 86% gross margin. The company raised the low end of its full‑year revenue outlook, reflecting confidence in its commercial execution and pipeline progress. Technically, the stock shows a bullish MACD crossover and an RSI of 61, with volume trending higher, suggesting continued buying pressure despite a neutral overall trend. However, valuation multiples remain extreme – a trailing PE of 93 versus an industry average of 26 and a price‑to‑book of nearly 80 – though a discounted cash‑flow model assigns a fair value of $8.06, implying roughly a 20% upside from the current $6.53 price. The balance sheet is heavily leveraged (debt‑to‑equity > 1,900) and the stock has experienced high 30‑day volatility (~40%) and a historic max drawdown of –46%, underscoring significant risk even as the market sentiment is in “Extreme Greed” territory.